Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia (Q36222910)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

chronic lymphocytic leukemia

9 February 2020

main subject

phase I clinical trial

0 references

0 references

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Brian K Link

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

George J Weiner

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

7

Tait D Shanafelt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

Timothy G Call

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

Clive S Zent

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

9

Neil E Kay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Brian J Smith

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

James E Wooldridge

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Deborah A Bowen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Thomas E Witzig

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

1 reference

19 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

211-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach

9 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

1 October 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Development of TLR9 agonists for cancer therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438221

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

1 October 2017

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F10428194.2011.608451

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F10428194.2011.608451

B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides

21 January 2018

1 reference

12 December 2020

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

12 December 2020

Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Cell-mediated immunity in chronic lymphocytic leukemia

1 reference

12 December 2020

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

12 December 2020

10.3109/10428194.2011.608451

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812536%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference